Healthcare Behaviour Strategy
Understanding a market isn't the same as changing it
Healthcare behaviour change rarely starts with more clinical data, it starts with understanding why people act the way they do. Most healthcare marketing research can tell you how things are today, and with good analysis, why they got that way. Where it usually stops short is the third, harder question: what will actually change it. That's the gap DeltaMV's Healthcare behaviour strategy work exists to close.
We describe our point of difference from traditional market research agencies as a simple progression — Describe, Understand, Shape — and it's the "Shape" stage, turning insight into a deliberate intervention, that defines everything in this practice.
HEALTHCARE BEHAVIOURAL INSIGHT:
BEHAVIOURAL SCIENCE IN HEALTHCARE, MADE USABLE
Behavioural science in healthcare is a genuinely complex field. Researchers have catalogued more than 150 distinct cognitive biases in healthcare decision-making; anchoring, status quo bias, loss aversion, social proof, and dozens more. Left as an academic list, that complexity is unusable for a commercial team under a deadline.
We've spent years distilling it into a simple, applicable model built around three levers:
Make it EASY
Remove the practical friction sitting between intention and action
Make it SOCIAL
Use the peer influence and networks a physician or patient already trusts
Make it EMOTIONAL
Move past a features-and-data pitch to the emotional stakes that actually drive a decision
This isn't theory for its own sake. It reframes the kind of problems a commercial team can solve with research, and gives brand and sales teams a genuinely new set of tools rather than more of the same tactics.
PHYSICIAN PRESCRIBING BEHAVIOUR AND
BARRIERS TO TREATMENT ADOPTION
Understanding physician prescribing behaviour sits at the centre of most of the work we do. Prescribing decisions are rarely as rational as a brand plan assumes, they're shaped by habit, risk perception, peer influence, administrative burden, and how confident a physician feels explaining a treatment choice to their patient.
In our work across diabetes, obesity, oncology, rare disease and other specialist areas, the same barriers to treatment adoption come up again and again:
Perceived risk and unfamiliarity
With a new mechanism, formulation, or treatment paradigm
Anchoring to the existing standard of care
Physicians default to the option they know, even when new data favours a change
Administrative and workflow burden
Prescribing, monitoring, or managing a new therapy
Undifferentiated positioning
Where a new molecule's efficacy and side-effect profile look too similar to existing options for a physician to justify switching
Gaps in confident communication
Physicians who don't feel equipped to explain a new option's value to a patient are slower to adopt it
PHYSICIAN ADOPTION OF NEW TREATMENTS:
FROM DATA SHEET TO DECISION
Treatment adoption in pharma rarely fails because the clinical data is weak — physicians usually already have that data. It fails because the decision to prescribe differently hasn't been made emotionally easy.
Understanding physician adoption of new treatments as a journey, rather than a single decision point, changes how we approach a launch or a switch strategy: mapping where a given physician sits on that journey, then designing the specific nudge that moves them along it.
HOW TO INCREASE TREATMENT ADOPTION
When clients ask us how to increase treatment adoption, we rarely start with more clinical evidence. Instead, our approach centres on the insights behavioural science delivers:
Re-framing value
Moving a molecule's story from a clinical efficacy/side-effect comparison to a differentiated value proposition built around the physician's and patient's actual experience
Building an emotional communication platform
Developing messaging and selling stories that connect a product's features to benefits that genuinely matter to the physician and their patients, not just to the data sheet
Reducing friction at the point of decision
Ecosystem shaping and practical tools that make the easier choice also the better one
Building physician confidence
Equipping the field team to answer the objections physicians actually raise, rather than the ones a brand plan assumes they'll raise
Persona development
Bringing prescribers to life as real people, described by their motivations, social networks and context, not just their specialty and prescribing volume
FROM BEHAVIOURAL MAPPING THROUGH TO THE SALES CALL
We translate this thinking into practical, hands-on work with brand and sales teams:
Behavioural mapping workshops
Identifying the current behavioural challenges along a patient's or physician's adoption journey, and applying behavioural science tools to generate strategies with measurable business impact
Emotional communication platforms
Moving field teams from talking about product features to communicating the emotional benefits that actually land
Integrating emotion into the sales call
Training field teams to use the emotional communication platform directly in calls, including live roleplay so reps leave ready to use it, not just aware of it
Behavioural science ideation
Working directly with brand and sales teams to apply behavioural nudges to their specific commercial challenges
We use workshops and qualitative research to turn clinician insights into practical tools for launch and communication planning. This can include defining clinician personas, identifying emotional benefits and pain points, and developing positioning statements, selling stories, call-opening questions, and field-team materials that can be applied across markets.
WHERE BEHAVIOURAL STRATEGY MEETS OMNICHANNEL
Delivering healthcare behavioural insight Vietnam pharma and life-sciences teams can act on starts with clear execution. Omnichannel excellence is a critical tool for executing behavioural strategy effectively. Changing behaviour doesn't stop with messaging — it extends to how, where, and how often you reach a physician.
We've extended our expertise in behaviour change into commercial effectiveness through OmniCompass™, our unique suite of tools built around four building blocks: content strategy, brand, channel optimisation, and metrics.
Within OmniCompass™, we run a structured programme that starts with foundational insight into target clinicians, followed by a baseline survey of key omnichannel metrics, an omnichannel excellence planning workshop, and ongoing tracking of those metrics over time. We measure success using five key metrics. Theseinclude; Touchpoint Equivalence Score — a measure of channel effectiveness for an individual prescriber —Effective Share of Voice, which combines touchpoint volume with channel effectiveness to enable a true cross-channel comparison, right through to preference share for a given patient profile, the ultimate outcome of any omnichannel activity.
In practice, this looks like structured workshops that help brand teams define, for every target HCP, the right channel, the right frequency, the right value, the right message, and the right time to share it. Thisturns a general omnichannel ambition into a specific, measurable engagement plan, and a behavioural insight into something a brand team can act on immediately.
Want to explore what a behavioural approach
could do for your next launch, switch strategy, or brand plan?
Get in touch to see how healthcare behaviour strategy can sharpen your next launch.
How savvy is your knowledge of human behaviour?
